Organogenesis stock at 0.78 euros before third-quarter results
Published on 11/05/2026 at 03:40 | Editorial responsibility: Rafael MĂĽller, Editor-in-Chief AD HOC NEWSOrganogenesis awaits quarterly results
- Organogenesis plans to publish third-quarter fiscal 2026 results after the market close on November 5.
- Management is scheduled to discuss the results and provide a corporate update during a conference call.
- The company develops regenerative medicine products for advanced wound care, surgical and sports medicine markets.
Organogenesis Holdings is scheduled to report its third-quarter fiscal 2026 financial results after the market close on Thursday, November 5, according to a company release published October 12. Management plans to discuss the quarter, provide a corporate update and take questions during a 5:00 p.m. Eastern Time conference call.
Organogenesis stock traded at 0.78 euros on Lang & Schwarz at 11:00 p.m. CET on Wednesday, November 4, 2026.
Results set the next catalyst
The earnings release will give investors a fresh view of demand after the company’s second-quarter report and its 2026 outlook. The scheduled call may also provide management’s latest comments on product performance, development programs and operating priorities.
The company’s October 12 release said it operates in advanced wound care and surgical and sports medicine. The company’s investor materials identify products including PuraPly, Affinity, Apligraf, Dermagraft, NuShield, NuCel and ReNu, serving hospitals, wound care centers, ambulatory surgery centers and physician offices.
Regenerative medicine portfolio
Organogenesis Holdings is a US healthcare company headquartered in Canton, Massachusetts. It develops, manufactures and markets regenerative medicine products for advanced wound management as well as surgical and sports medicine applications. Its portfolio spans wound coverings, bioengineered tissue products, antimicrobial barriers and products intended to support soft-tissue and orthopedic procedures.
Organogenesis Holdings at a glance
- Company: Organogenesis Holdings Inc.
- ISIN: US68621F1021
- Ticker: ORGO
- Home exchange: Nasdaq
- Lang & Schwarz price: 0.78 euros on November 4, 2026 at 11:00 p.m. CET
- Market capitalization: 111.95 million US dollars as of November 4, 2026 at 9:00 p.m. UTC
- 52-week range: 0.73 to 7.08 US dollars
Organogenesis Holdings’ press release said the third-quarter results would be released after the market close on November 5.
US equities trade in the broader S&P 500 market environment; see current S&P 500 market reports.
